WarenkorbDrucken
Falk Foundation | Dr. Falk
Sie befinden sich hier:  PatientsDiseases and TreatmentLiver DiseasesAutoimmune Hepatitis
Further Information

Primary Biliary Cirrhosis/Cholangitis

Primary Sclerosing Cholangitis

Fatty Liver Disease

Hepatitis

Autoimmune Hepatitis

Liver Cirrhosis

Hepatic Encephalopathy

Hepatocellular Carcinoma


Autoimmune Hepatitis

Autoimmune hepatitis (AIH) is a form of chronic hepatitis. The patient suffers from non-specific symptoms such as fatigue, dark urine, and discoloration of stools, upper abdominal discomfort or skin rashes. Blood findings commonly include antibodies (IgG) and “auto-antibodies”, the latter being antibodies that attack the body’s own tissues. A tissue sample is generally taken to confirm diagnosis and exclude other liver diseases. In 80% of patients women between 10 and 30 years and those between 40 and 55 years are affected.
AIH responds quickly and reliably to immunosuppressive treatment. Corticosteroids (budesonide/prednisolone) and the immunosuppressant azathioprine are used for acute and long-term treatment. The dosage of corticosteroids can be reduced by concomitant administration of azathioprine. For long-term treatment azathioprine can also be used alone. Treatment must be continued over several years and should not be discontinued too early in order to prevent recurrence. Recent data demonstrate superior efficacy and tolerance in acute treatment of AIH for budesonide versus the conventional steroid prednisolone. Used as maintenance treatment, budesonide has considerably reduced steroid-related adverse effects with comparable efficacy.


Patienten für laufende Studie zu MORBUS CROHN gesucht!

Klinische Studie zur Beurteilung eines neuen, sich in der Erprobung befindlichen biologischen Medikaments. Der Name der Studie ist TRUST-2, was für „TRichUris Suis ova Trial“ steht.

Mehr als 200 Patienten mit MORBUS CROHN haben das sich in der Erprobung befindende Studienmedikament bisher in klinischen Studien eingenommen.

Die Studien zeigen eine Abnahme der Krankheitsaktivität und in der Mehrzahl der Fälle wurde Remission (beschwerdefreie Phase) erzielt. Die bisher beobachteten Nebenwirkungen betrafen zumeist den Verdauungstrakt.